Shields Jerry A, Shields Carol L, Freire Jorge E, Brady Luther W, Komarnicky Lydia
Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, U.S.A.
Ophthalmic Plast Reconstr Surg. 2003 Mar;19(2):91-5. doi: 10.1097/01.IOP.0000056020.66654.33.
To describe the principles and preliminary results of plaque brachytherapy for selected orbital malignancies.
A custom-designed Iodine-125 plaque, designed to deliver a target dose of 50 Gray, was placed surgically in the region from which an orbital malignancy was partially resected. The mean dose to the target area was 50 Gray. The initial and follow-up patient data were reviewed.
Of the 8 patients, the diagnosis was adenoid cystic carcinoma of the lacrimal gland (4 cases), orbital invasion by basal cell carcinoma (2), orbital extension of conjunctival melanoma (1), and metastatic carcinoma (1). Of the 4 with adenoid cystic carcinoma, there was microscopic residual tumor after excision and orbital exenteration was considered. Three have tumor control with follow-up of 1, 3, and 6 years. One patient required exenteration for recurrence separate from the field of brachytherapy and is free of tumor after 10 years. All 4 patients are alive and well with tumor control. Of the 2 patients with orbital extension of basal cell carcinoma, tumor control without recurrence has been achieved in both after 2 years. The patient with orbital metastasis responded to plaque radiotherapy, with no orbital recurrence, but died of systemic metastasis. The patient with orbital melanoma had local orbital recurrence separate from the area of irradiation and is currently being treated for systemic metastasis.
Based on preliminary observations, plaque radiotherapy appears to be a reasonable alternative to exenteration and external irradiation for selected orbital malignancies.
描述针对特定眼眶恶性肿瘤的敷贴近距离放射治疗的原则及初步结果。
将定制设计的碘-125敷贴(设计目标剂量为50格雷)通过手术放置于眼眶恶性肿瘤部分切除后的区域。靶区的平均剂量为50格雷。对患者的初始及随访数据进行了回顾。
8例患者中,诊断为泪腺腺样囊性癌(4例)、基底细胞癌眼眶侵犯(2例)、结膜黑色素瘤眼眶扩展(1例)以及转移性癌(1例)。4例腺样囊性癌患者中,切除术后有镜下残留肿瘤,考虑行眼眶内容物剜除术。3例实现了肿瘤控制,随访时间分别为1年、3年和6年。1例患者因近距离放射治疗区域外的复发需要进行眼眶内容物剜除术,10年后无肿瘤。所有4例患者均存活且肿瘤得到控制。2例基底细胞癌眼眶扩展患者,2年后均实现了无复发的肿瘤控制。眼眶转移患者对敷贴放疗有反应,无眼眶复发,但死于全身转移。眼眶黑色素瘤患者在放疗区域外出现局部眼眶复发,目前正在接受全身转移的治疗。
基于初步观察,对于特定眼眶恶性肿瘤,敷贴放疗似乎是眼眶内容物剜除术和外照射的合理替代方法。